Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?
Bioengineering · 30.09.2023 · 10 (10) · 1149
DOI: 10.3390/bioengineering10101149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioengineering, online erschienen am 30.09.2023. Verfasst von Lukas Marschall und 6 weiteren Autor:innen. Beteiligte Einrichtung: TU Wien, Faculty of Technical Chemistry, Research Unit Biochemical Engineering, Gumpendorferstrasse 1a, 1060 Vienna, Austria. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TU Wien.
Abstract (Originalsprache)
Temperature downshifts are the gold standard when setting up control strategies for mammalian cell culture processes. These shifts are performed to prolong production phases and attain heightened levels of productivity. For the development of biosimilars, however, the bottleneck is in achieving a prespecified product quality. In a late-stage development project, we investigated the impact of temperature shifts and other process parameters with the aim of optimizing the glycosylation profile of a monoclonal antibody (mAb). We applied a design of experiments approach on a 3 L scale. The optimal glycosylation profile was achieved when performing a temperature upshift from 35.8 °C to 37 °C. Total afucosylated glycan (TAF) decreased by 1.2%, and galactosylated glycan species (GAL) increased by up to 4.5%. The optimized control strategy was then successfully taken to the manufacturing scale (1000 L). By testing two sets of set points at the manufacturing scale, we demonstrated that the statistical models predicting TAF and GAL trained with small-scale data are representative of the manufacturing scale. We hope this study encourages researchers to widen the screening ranges in process development and investigate whether temperature upshifts are also beneficial for other mAbs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- TU Wien, Faculty of Technical Chemistry, Research Unit Biochemical Engineering, Gumpendorferstrasse 1a, 1060 Vienna, Austria.
- Körber Pharma Austria GmbH, Mariahilfer Straße 88A/1/9, 1070 Vienna, Austria.
- Dr. Reddy's Laboratories Ltd., Biologics, Survey No. 47, Bachupally, Hyderabad 500090, India.
ORCID-Profile: Chitti Babu Gottimukkala, Veerabhadra Madurai Veeraraghavan, Christoph Herwig
Förderung
- TU Wien
Zitieren
APA
Marschall, L., Gottimukkala, C. B., Kayal, B., Veeraraghavan, V. M., Mandal, S. K., Bandyopadhyay, S., & Herwig, C. (2023). Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?. Bioengineering, 10(10), 1149. https://doi.org/10.3390/bioengineering10101149
Vancouver
Marschall L, Gottimukkala CB, Kayal B, Veeraraghavan VM, Mandal SK, Bandyopadhyay S, et al. Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?. Bioengineering. 2023;10(10):1149. doi:10.3390/bioengineering10101149
BibTeX
@article{Marschall2023,
author = {Marschall, Lukas and Gottimukkala, Chitti Babu and Kayal, Biswajit and Veeraraghavan, Veerabhadra Madurai and Mandal, Samir Kumar and Bandyopadhyay, Suman and Herwig, Christoph},
title = {Temperature Upshifts in Mammalian Cell Culture: A Suitable Strategy for Biosimilar Monoclonal Antibodies?},
journal = {Bioengineering},
year = {2023},
volume = {10},
number = {10},
pages = {1149},
doi = {10.3390/bioengineering10101149}
}
EUVIMED